# PT-141 for Men: The Off-Label Erectile Research (Not FDA-Approved)

> PT-141 for men is off-label and investigational. The early intranasal/subcutaneous erectile research, the disputed 2008 sildenafil-salvage study (Expression of Concern), and the Phase 2 combination pipeline.

Bremelanotide is approved only for HSDD in premenopausal women. The male and erectile evidence is early-phase and investigational — scoped honestly, with its disputed studies flagged.

## The short version

PT-141 for men is not approved. Bremelanotide is FDA-approved only for low sexual desire (HSDD) in premenopausal women; using it in men or for erectile dysfunction (ED) is off-label, and the evidence is early-stage. The earliest research did show erectile responses in men, and because PT-141 works in the brain while standard ED drugs work on blood flow, a combination of the two is now being tested. But one influential older study later received a formal integrity notice, and no large modern trial has established the male use. Treat everything here as investigational research, not established benefit.

## Why the Male Use Is Off-Label

The approval is narrow by design: `NDA 210557` covers acquired, generalized HSDD in premenopausal women, and nothing else [6]. Use in men, for erectile dysfunction, or in postmenopausal women is off-label and not supported by the approval. There is real early-phase data in men, but "early-phase" is the operative phrase — it is investigational, not established, and there is no regulatory finding of safety or efficacy for the male indication [6].

That distinction is the whole point of this page. The desire mechanism that drove the approved indication is the same central [how PT-141 works in the brain](/research) action being explored in men — but a shared mechanism is not an approval.

## The Early Erectile Research

The foundational pharmacology established the male signal first. In rats, nonhuman primates, and men with erectile dysfunction, systemic PT-141 produced rapid, dose-dependent erectile activity and activated hypothalamic neurons, consistent with a central mechanism [1]. Early development used intranasal and intravenous routes; the intranasal route was later discontinued due to pharmacokinetic variability [6].

In early intranasal dose-escalation research in men, a statistically significant erectile response was reported above roughly `7 mg`, with dosing explored up to `~20 mg` [6]. This established proof-of-concept for a central erectile mechanism — but proof-of-concept in early development is exactly that, not a finished indication.

## The Disputed 2008 Sildenafil-Salvage Study

One frequently-cited male study must be read with its caveat attached. A `2008` randomized, double-blind, placebo-controlled trial reported that intranasal bremelanotide `10 mg` produced positive clinical results in `33.5%` of sildenafil non-responders versus `8.5%` on placebo [13]. On its face that is a striking salvage signal in men who had not responded to a PDE-5 inhibitor.

But a `2023` Expression of Concern was published for this study [13]. An Expression of Concern is a formal editorial notice that a publication's integrity is in question. The honest handling is to disclose it every time the study is cited: treat the `33.5%` vs `8.5%` finding as **disputed**, not as a reliable result. This site flags it rather than quietly dropping it, because a researcher weighing the male evidence needs to know the caveat exists.

## The Active Combination Pipeline

The current direction for the male and erectile setting is a combination, not bremelanotide alone. Because PT-141 works centrally and PDE-5 inhibitors work peripherally on blood flow, the two mechanisms are complementary in principle [1].

In `June 2024`, the developer announced initiation of a Phase 2 study (~`50` patients) of bremelanotide co-administered with a PDE-5 inhibitor for erectile dysfunction in PDE-5-inhibitor non-responders, with a co-formulation IND and a potential Phase 3 planned [14]. This is sourced from a corporate press release, so it supports a pipeline and development-status statement only — not an efficacy claim. The male and erectile use remains off-label and investigational while that program runs.

---

A precision-metrology readout of the bremelanotide record — each measured value logged to its study and tagged in-spec or disputed, the effect-size debate kept beside the number it qualifies and the field reports fenced off the calibrated panel; no clinic behind the instrument and nothing here dosed, dispensed, or sold.